CBLL
Ceribell, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$25.58
−7.47%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$27.47
From 52W high−7.47%
Volume212371.00
Market cap$981.52M
P/E (TTM)—
P/S (TTM)9.6x
Div yield—
Key dataOct 16, 2026
Open
$27.47
From 52W high
−7.47%
Volume
212371.00
Market cap
$981.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.9x
P/E (TTM)
—
RSI (14)
57.7
MomentumView details →
1D Return
−7.47%
YTD Return
+18.47%
SummaryUpdated Jun 1, 2026
CeriBell, Inc. (NASDAQ:CBLL) is a medical device company founded in 2014 and based in Sunnyvale, California. Originally incorporated as Brain Stethoscope, Inc., the company changed its name to CeriBell in August 2015. CeriBell has developed artificial intelligence-powered point-of-care electroencephalography (EEG) technology designed to detect and monitor neurological conditions in acute care settings. The company went public and has established itself as a leader in seizure detection technology, with its systems having been used on over 200,000 patients across more than 500 active hospital accounts.
Similar companies
Latest newsMore news →
Ceribell CFO Scott Blumberg exercised options for 846 shares at $9.41 and sold the same 846 shares for $21,150 on September 15, 2026, under a Rule 10b5-1 plan adopted December 12, 2025.29d agoCeribell President and CEO Chao Xingjuan sold 6,068 shares of Ceribell common stock at $24.02 per share, totaling $145,753, on August 21, 2026, to cover tax withholding obligations related to RSU vesting.52d agoCeriBell, Inc. held its Q2 2026 earnings call on August 11, 2026, to discuss financial results.66d ago